Actemra (Tocilizumab) Market 2026–2035 expanding with immunology treatments

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Actemra (Tocilizumab) Market Over The Period 2026–2030?

The actemra (tocilizumab) market size has experienced substantial expansion in recent years. It is anticipated to grow from $5.71 million in 2025 to $6.32 million in 2026, registering a compound annual growth rate (CAGR) of 10.6%. The market’s past growth can be attributed to the recognized significance of IL-6 in inflammation, the rising incidence of rheumatoid arthritis, favorable outcomes from clinical trials, the increasing adoption of biologics in tertiary hospitals, and regulatory approvals across multiple indications.

The market size for actemra (tocilizumab) is anticipated to experience swift expansion over the coming years. By 2030, it is projected to reach $9.34 million, demonstrating a compound annual growth rate (CAGR) of 10.3%. This projected growth is driven by factors such as a greater prevalence of autoimmune diseases, the drug’s application in additional inflammatory conditions, the proliferation of biologic infusion centers, enhanced rates of early diagnosis, and improved availability of biologic therapies. Key trends expected during this period involve broadened application in autoimmune and inflammatory disorders, increasing utilization for managing cytokine release syndrome, more frequent hospital-based administration of biologics, a heightened emphasis on early IL-6 targeted intervention, and strengthened long-term safety surveillance for biologics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19849&type=smp

Which Major Factors Are Driving The Expansion Of The Actemra (Tocilizumab) Market?

The increasing occurrence of rheumatoid arthritis is projected to boost the expansion of the actemra (tocilizumab) market in the foreseeable future. Rheumatoid arthritis is defined as a persistent autoimmune disorder characterized by joint inflammation, damage, and a diminished quality of life, impacting millions worldwide. Conditions like smoking, obesity, environmental exposures, and hormonal imbalances contribute to rheumatoid arthritis. actemra (tocilizumab) serves as a treatment for rheumatoid arthritis, working to lessen inflammation and avert joint deterioration through the inhibition of the interleukin-6 (IL-6) receptor, especially beneficial for individuals unresponsive to alternative therapies. As an illustration, data released by the National Institute for Health and Care Research (NIHR), a UK government agency, in April 2024, indicated that around 700,000 individuals in the UK are currently afflicted with rheumatoid arthritis. Furthermore, a June 2024 report from the Australian Institute of Health and Welfare, an Australian national agency, noted that approximately 514,000 people (2.0% of the population) in Australia had rheumatoid arthritis in 2022. By 2023, this condition was responsible for 2.0% of the overall disease burden and 16% of the disease burden specifically attributed to musculoskeletal conditions. Moreover, rheumatoid arthritis contributed to 1,322 fatalities in 2022, translating to 5.1 deaths per 100,000 people and accounting for 0.7% of all recorded deaths. Consequently, the growing incidence of rheumatoid arthritis is a significant impetus for the actemra (tocilizumab) market.

How Is The Actemra (Tocilizumab) Market Divided Into Its Major Segments?

The actemra (tocilizumab) market covered in this report is segmented –

1) By Product Type: Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%

2) By Dosage: Injection, Solution, Concentrate

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By Application: Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), Rheumatoid Arthritis (RA)

How Are Trends Transforming The Actemra (Tocilizumab) Market Landscape?

Major companies operating in the actemra (tocilizumab) market are concentrating on developing advanced solutions, such as tocilizumab biosimilars, to achieve a competitive edge in the industry. These tocilizumab biosimilars are approved for the treatment of autoimmune diseases and COVID-19, providing an alternative to the original drug Actemra. For instance, in November 2023, Fresenius Kabi, a Germany-based healthcare company, introduced Tyenne, which is the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne has received approval for treating multiple inflammatory and immune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and COVID-19.

Who Are The Prominent Organizations Shaping The Actemra (Tocilizumab) Market?

Major companies operating in the actemra (tocilizumab) market are Roche Holding AG, Fresenius Kabi

Read the full actemra (tocilizumab) market report here:

https://www.thebusinessresearchcompany.com/report/actemra-tocilizumab-global-market-report

Which Region Currently Holds The Largest Share Of The Actemra (Tocilizumab) Market?

North America was the largest region in the actemra (Tocilizumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actemra (tocilizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Actemra (Tocilizumab) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19849&type=smp

Browse Through More Reports Similar to the Global Actemra (Tocilizumab) Market 2026, By The Business Research Company

Tofacitinib Market Report 2026

https://www.thebusinessresearchcompany.com/report/tofacitinib-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795